Boston Scientific Gives Up On Lotus Edge TAVR

The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.

Hand holding scissors to cut banknotes
• Source: shutterstock.com

Boston Scientific is recalling all unused Lotus Edge transcatheter aortic valve replacement (TAVR) systems and is immediately retiring the entire Lotus technology platform, including all commercial, clinical, research, development and manufacturing activities related to the Lotus TAVR technology.

The company initiated a global, voluntary recall of Lotus Edge on 17 November due to ongoing “complexities” with the valve’s...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Strategy

More from Business